Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 24402627)

1.

[Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease].

Visciano B, Nazzaro P, Tarantino G, Taddei A, Del Rio A, Mozzillo GR, Riccio E, Capuano I, Pisani A.

G Ital Nefrol. 2013 Sep-Oct;30(5). pii: gin/30.5.7. Italian.

PMID:
24402627
2.

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2014 Nov;29(11):2075-84. doi: 10.1093/ndt/gfu201. Epub 2014 Jun 2.

3.

The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.

Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2014 Apr;29(4):843-50. doi: 10.1093/ndt/gft424. Epub 2013 Oct 29.

4.

Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.

Nephrol Dial Transplant. 2013 Apr;28(4):953-64. doi: 10.1093/ndt/gfs528. Epub 2012 Dec 5.

5.

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM.

Am J Kidney Dis. 2015 May;65(5):728-36. doi: 10.1053/j.ajkd.2014.10.014. Epub 2014 Nov 4.

6.

Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial.

Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL.

BMC Nephrol. 2013 Mar 20;14:64. doi: 10.1186/1471-2369-14-64.

7.

Use of intravenous iron supplementation in chronic kidney disease: an update.

Macdougall IC, Geisser P.

Iran J Kidney Dis. 2013 Jan;7(1):9-22. Review.

8.

Ferumoxytol for treating iron deficiency anemia in CKD.

Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ.

J Am Soc Nephrol. 2008 Aug;19(8):1599-605. doi: 10.1681/ASN.2007101156. Epub 2008 Jun 4.

9.

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD.

Nephrol Dial Transplant. 2011 May;26(5):1599-607. doi: 10.1093/ndt/gfq613. Epub 2010 Oct 7.

10.

Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease.

Hazara AM, Bhandari S.

J Clin Pharm Ther. 2015 Feb;40(1):20-3. doi: 10.1111/jcpt.12218. Epub 2014 Oct 10.

PMID:
25302541
11.

Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.

Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.

Clin Nephrol. 2014 Jun;81(6):419-26. doi: 10.5414/CN108166.

PMID:
24691014
12.

Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.

Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U.

Am J Kidney Dis. 2008 Nov;52(5):897-906. doi: 10.1053/j.ajkd.2008.05.033. Epub 2008 Oct 8. Review.

PMID:
18845368
13.

Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.

Mircescu G, Gârneata L, Capusa C, Ursea N.

Nephrol Dial Transplant. 2006 Jan;21(1):120-4. Epub 2005 Sep 6.

14.

Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis.

Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV.

Kidney Int. 1999 May;55(5):1891-8.

15.

Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease.

Liles AM.

Am J Health Syst Pharm. 2012 Jul 15;69(14):1206-11. doi: 10.2146/ajhp110231. Review.

PMID:
22761074
16.

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ.

Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28.

17.

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.

Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J.

Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23.

18.

Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.

Goldstein SL, Morris D, Warady BA.

Am J Kidney Dis. 2013 Apr;61(4):588-97. doi: 10.1053/j.ajkd.2012.10.019. Epub 2012 Dec 12.

PMID:
23245582
19.

Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.

Toblli JE, Lombraña A, Duarte P, Di Gennaro F.

J Am Coll Cardiol. 2007 Oct 23;50(17):1657-65.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk